G1 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 04:03 pm EDT
Share
G1 Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 12.3 million compared to USD 23.58 million a year ago. Net loss was USD 18.2 million compared to USD 25.27 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.59 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.59 a year ago.
For the nine months, revenue was USD 67.64 million compared to USD 41.05 million a year ago. Net loss was USD 37.09 million compared to USD 113.91 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 2.67 a year ago. Diluted loss per share from continuing operations was USD 0.72 compared to USD 2.67 a year ago.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
G1 THERAPEUTICS, INC. 
